A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
Status:
Withdrawn
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ustekinumab in Chinese participants
with active systemic lupus erythematosus (SLE) who have not adequately responded to one or
more standard-of-care treatments.